Table 1. Demographic, clinical and molecular pathology characteristics of the patients enrolled in the clinical trial.
| CODE | Sex | ECOG | Metastatic sites | Previous treatment lines | K-ras | HLA | Treatment courses | MANT | Type of response |
|---|---|---|---|---|---|---|---|---|---|
| MFA/A/DL1 | F | 0 | Liver, lung | 11 | Wt | A2 | 3 | Na | SD |
| RAA/A/DL1 | F | 0 | Peritoneum, nodes | 7 | Wt | A2 | 3 | Na | PD |
| ASA/A/DL1 | M | 0 | Liver, Lung | 3 | Wt | A2 | 3 | Na | SD |
| LVA/A/DL2 | M | 0 | Liver, Lung, nodes | 7 | Wt | A11 | 6 | Na | SD |
| SGA/A/DL2 | M | 0 | Peritoneum, nodes | 4 | Wt | A25 | 6 | Na | SD |
| ZSA/A/DL3 | F | 0 | Nodes, Adrenal | 3 | Wt | A2 | 48 | Na | PR |
| PNA/A/DL3 | F | 0 | Lung, bones | 3 | Mut | A1 | 3 | Na | SD |
| SNA/A/DL3 | M | 2 | Liver, lung | 3 | Mut | A2 | 3 | Na | PD |
| GL/B/DL2 | F | 0 | Liver, abdomen | 3 | Mut | A24 | 3 | Na | PD |
| PP/B/DL2 | F | 0 | Lung, liver abdomen | 3 | Wt | A2 | 3 | Na | SD |
| FG/B/DL2 | M | 0 | Abdomen, nodes | 3 | Wt | A24 | 3 | Na | PD |
| MM/B/DL3 | M | 1 | Lung, liver abdomen | 3 | Mut | A1 | 3 | Na | SD |
| LM/C/DL1 | F | 2 | Peritoneum, lung, liver | 2 | Mut | A24 | 7 | 2 | SD |
| CV/C/DL1 | M | 1 | Peritoneum, lung, liver | 6 | Mut | A3 | 6 | 0 | PD |
| BF/C/DL1 | M | 2 | Peritoneum, lung, liver | 3 | Mut | A11 | 3 | 0 | PD |
| CL/C/DL2 | F | 0 | Peritoneum, nodes | 3 | Mut | A2 | 12 | 1 | PD |
| FA/C/DL2 | F | 2 | Colon, lung, liver | 6 | Wt | A11 | 11 | 0 | SD |
| SA/C/DL2 | M | 0 | Lung, liver, nodes | 5 | Wt | A2 | 12 | 2 | PR |
| SS/C/DL3 | F | 0 | Brain, lung, liver, nodes | 5 | Mut | A23 | 12 | 3 | PR |
| BA/C/DL3 | F | 1 | Colon, lung, liver, nodes | 2 | Mut | A2 | 11 | 0 | SD |
| SA/C/DL3 | F | 2 | Peritoneum, lung, liver | 5 | Mut | A2 | 12 | 0 | PD |
| DA/C/DL3 | F | 2 | Peritoneum, lung, liver | 4 | Mut | A1 | 10 | 0 | PD |
| MP/C/DL3 | M | 1 | Peritoneum, lung, liver | 6 | Mut | A2 | 6 | 0 | SD |
| PM/C/DL3 | M | 1 | Peritoneum, lung, liver | 2 | Mut | A11 | 12 | 3 | SD |
| MU/C/DL3 | F | 1 | Soft tissue, nodes | 2 | Wt | A24 | 12 | 14 | SD |
| PA/C/DL3 | M | 1 | Peritoneum, lung, liver | 7 | Wt | A2 | 11 | 3 | PR |
| CA/C/DL3 | M | 2 | Peritoneum, lung, liver | 3 | Mut | NA | 6 | 0 | PD |
| BG/C/DL3 | F | 0 | Peritoneum, lung, liver | 3 | Wt | A2 | 10 | 8 | SD |
| NR/C/DL3 | F | 2 | Peritoneum, lung, liver | 2 | Mut | A2 | 3 | 0 | PD |
| SR/C/DL0 | M | 0 | Lung, liver | 3 | Wt | A23 | 12 | 5 | SD |
| DG/C/DL0 | F | 0 | Lung, liver | 3 | Wt | A33 | 10 | 5 | PR |
| BL/C/DL0 | F | 0 | Lung, liver | 2 | Wt | A3 | 10 | 9 | SD |
| ML/C/DL0 | F | 0 | Peritoneum, lung, liver | 2 | Mut | A2 | 10 | 9 | SD |
| VP/C/DL0 | M | 1 | lung, liver | 2 | Wt | A2 | 7 | 1 | PD |
| PG/C/DL0 | M | 1 | lung, liver | 2 | Wt | A24 | 9 | 12 | SD |
| SA/C/DL0 | M | 2 | Peritoneum, lung, liver | 3 | Wt | A1 | 7 | 0 | PD |
| MA/C/DL0 | M | 0 | lung, liver | 2 | Mut | A1 | 9 | 32 | PR |
| PA/C/DL0 | M | 0 | lung, liver | 2 | Wt | A3 | 11 | 14 | PR |
| DL/C/DL0 | F | 0 | Peritoneum, lung, liver | 3 | Wt | A2 | 9 | 4 | SD |
| VC/C/DL0 | M | 0 | Peritoneum, lung, liver | 2 | mut | A23 | 10 | 7 | PR |
| PA/C/DL0 | F | 1 | Peritoneum, lung, liver | 3 | Wt | A23 | 9 | 4 | SD |
Legend: ECOG, Eastern Cooperative Oncology Group performance status; Wt, Wild type; Mut, Mutated; SD, Stabilized Disease; PR, Partial Response; PD, Progressive Disease; MANT, Maintainance Therapy duration in months; Na; not achieved.